Chalcogen Or Nitrogen Attached Indirectly To The Phenothiazine Ring Nitrogen By Acyclic Nonionic Bonding Patents (Class 514/226.2)
-
Publication number: 20090111792Abstract: Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a tricyclic antidepressant.Type: ApplicationFiled: October 16, 2008Publication date: April 30, 2009Applicant: AlgoRxInventors: Ronald M. Burch, Richard B. Carter, Jeff Lazar
-
Publication number: 20090075974Abstract: Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a 5-HT2C receptor. Preferably the binding activity (pKi) of the 5-HT2A receptor antagonist to the 5-HT2A receptor is at least 7.0, and more preferably at least 8.0. The present invention also provides a method of identifying a candidate substance for prophylactic and therapeutic agent for pancreatitis, comprising determining whether a test substance has a 5-HT2A receptor antagonistic activity.Type: ApplicationFiled: April 27, 2006Publication date: March 19, 2009Applicant: UMN Pharma Inc.Inventors: Isamu Yamaguchi, Kentaro Hamada, Yasunari Kashihara
-
Publication number: 20090075960Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Applicants: THE HOSPITAL FOR SICK CHILDREN, McMASTER UNIVERSITYInventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
-
Publication number: 20090062254Abstract: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.Type: ApplicationFiled: October 3, 2008Publication date: March 5, 2009Applicant: ALEXZA PHARMACEUTICALS, INC.Inventors: Ron L. Hale, Peter M. Lloyd, Amy T. Lu, Patrik Munzar, Joshua D. Rabinowitz, Roman Skowronski
-
Publication number: 20090054419Abstract: This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R1 and R9 is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).Type: ApplicationFiled: March 28, 2007Publication date: February 26, 2009Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Publication number: 20090012061Abstract: The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.Type: ApplicationFiled: September 9, 2005Publication date: January 8, 2009Inventors: Timothy A. Blizzard, Carolyn A. Buser-Doepner, Douglas E. Frantz, Kelly Hamilton, Myle Hoang, Ling Lee, Christopher R. Moyes, Jerry A. Murry, Arash Soheili
-
Publication number: 20090005357Abstract: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.Type: ApplicationFiled: September 11, 2008Publication date: January 1, 2009Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Miodrag Radulovacki, David W. Carley
-
Publication number: 20080305186Abstract: The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline.Type: ApplicationFiled: June 11, 2007Publication date: December 11, 2008Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Harold R. Garner, Mounir Errami
-
Publication number: 20080280886Abstract: Disclosed herein are urea-based 5-HT receptor modulators, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of 5-HT receptor-mediated disorders.Type: ApplicationFiled: May 8, 2008Publication date: November 13, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20080269206Abstract: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-6 or encompassed by formulas I-VI) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.Type: ApplicationFiled: March 28, 2008Publication date: October 30, 2008Inventors: Michael Geoffrey Neil Russell, Huw David Vater, Jacqueline Anne Macritchie, Kevin James Doyle, David Brown, Joanne Peach
-
Publication number: 20080269205Abstract: The present invention presents a method of preventing vertical transmission of an infectious disease comprising: (a) applying a photosensitizing composition to host tissues of birth canal of a mother during the intrapartum period; and (b) applying light to the host tissues after the step (a) at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate infectious disease microorganisms that come into contact with the host tissues. The infectious disease may be caused by human immunodeficiency virus type 1, hepatitis B virus, hepatitis C virus, Group B Streptococcus, cytomegalovirus, Listeria monocytogenes, Chiamydia trachomatis, Escherichia coli, herpes simplex virus, Epstein-Barr virus, Toxoplasma gondii, human papilloma virus, and Candida.Type: ApplicationFiled: October 23, 2007Publication date: October 30, 2008Inventors: Nicolas G. Loebel, Roger Andersen
-
Publication number: 20080261960Abstract: The present invention relates to a phenothiazinium compound of Formula (I): wherein: A and B each independently is in which R? and R? each independently is a linear, branched or cyclic hydrocarbon group, or R? and R? together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring; and where XP? is a counteranion and P is 1, 2 or 3; except for the compounds in which A and B are both either —N(CH3)2 or —N(CH2CH3)2 for use in a treatment that requires removal, deactivation or killing of unwanted tissues or cells. The invention also relates to compositions comprising the compounds of Formula I, to selected compounds of Formula I, use of the compounds of Formula I as medicaments and as a PDT agent or a photodiagnostic agent, a conjugate or composite formed between a compound of Formula I and a polymer; and to a method for sterilising fluids in which the fluid is passed over the conjugate or composite whilst it is illuminated.Type: ApplicationFiled: April 4, 2008Publication date: October 23, 2008Applicant: Photopharmica LimitedInventors: Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, Richard George Tunstall, David John Howard Roberts, David Ian Vernon
-
Publication number: 20080254130Abstract: The present invention relates to a topical method of treatment for dysfunction of certain dermal enzymes, and the treatment of skin condition or disorder caused by said dysfunction. The said method of treatment consists of (i) an extra-cellular, matrix metalloprotease regulating agent, and (ii) an intra-cellular ubiquitin—proteasome regulating agent, and (iii) an epidermal melanocyte-regulating agent; and, wherein, said extra-cellular agent, said intracellular agent, and said epidermal agent can, surprisingly and unexpectedly, be a single multi-function compound having chemical formula (I).Type: ApplicationFiled: June 14, 2008Publication date: October 16, 2008Applicant: BIODERM RESEARCHInventor: SHYAM K. GUPTA
-
Publication number: 20080234254Abstract: The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group.Type: ApplicationFiled: June 7, 2005Publication date: September 25, 2008Applicant: UNIVERSITY OF LEEDSInventors: Ronald Grigg, Andrew Cook
-
Publication number: 20080207604Abstract: The present invention relates to methods for the detection of substances capable of modulating or inhibiting pathological tau-tau protein association. The methods of the present invention are particularly useful in screening substances for the prophylaxis and treatment of Alzheiemer's disease.Type: ApplicationFiled: October 31, 2007Publication date: August 28, 2008Inventors: Claude Michel Wischik, Patricia Carol Edwards, Charles Robert Harrington, Martin Roth, Aaron King
-
Publication number: 20080207593Abstract: A once daily formulation containing the combination of a non-sedating or selective antihistamine (Loratadine) with a sedating or non-selective antihistamine (Chlorpheniramine) administered at bed-time has demonstrated greater efficacy in relieving allergic symptoms than Loratadine alone.Type: ApplicationFiled: August 20, 2007Publication date: August 28, 2008Inventors: Michael Heffernan, Jane C. Hirsh, Roman V. Rariy
-
Patent number: 7414128Abstract: The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, preferably (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparation and its use as therapeutic agent.Type: GrantFiled: March 14, 2005Date of Patent: August 19, 2008Assignees: Dr. Reddy's Laboratories, Limited, Dr. Reddy's Laboratories, Inc.Inventors: Søren Ebdrup, Petra Christine Lugstein
-
Patent number: 7407953Abstract: A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound of Formula (1) to a wound site or the skin, and optionally exposing the wound site or skin to light.Type: GrantFiled: March 20, 2007Date of Patent: August 5, 2008Assignee: Photopharmica LimitedInventors: Stanley Beames Brown, Cassandra Clare O'Grady
-
Patent number: 7393843Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.Type: GrantFiled: May 19, 2005Date of Patent: July 1, 2008Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Bornemann, Guenter Trummlitz, Bernd Beck, Frank Sams-Dodd, Dagmar Kugler, Klaus Klinder, Cornelia Dorner-Clossek, Marcus Kostka
-
Publication number: 20080026081Abstract: The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.Type: ApplicationFiled: November 19, 2004Publication date: January 31, 2008Inventors: Axel Unterbeck, Michael De Vivo, Gregory M. Rose
-
Patent number: 7323461Abstract: The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans. More specifically, the present invention concerns the use of MB or a related compound to prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor, such as sildenafil citrate, and a NO-donor, such as L-arginine, or an organic nitrate, such as nitroglycerin.Type: GrantFiled: March 28, 2003Date of Patent: January 29, 2008Assignee: Montreal Heart InstituteInventors: Martin Juneau, Jean-François Tanguay, Denis Brouillette
-
Patent number: 7320985Abstract: A method for stabilizing an arylcarboxylic acid, which comprises adding a heterocyclic base to the arylcarboxylic acid or a pharmacologically acceptable salt thereof, a stabilizer thereof and an aqueous solution containing a stabilized arylcarboxylic acid. According to the stabilization method of the present invention, arylcarboxylic acid and pharmacologically acceptable salts thereof, particularly pranoprofen, can be stabilized at every temperature range, particularly at lower temperatures, thereby making the production of an aqueous solution to be used as an eye drop, nasal drop, ear drop and the like possible.Type: GrantFiled: July 23, 2003Date of Patent: January 22, 2008Assignee: Senju Pharmaceutical Co., Ltd.Inventor: Shirou Sawa
-
Patent number: 7148216Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.Type: GrantFiled: December 28, 2004Date of Patent: December 12, 2006Assignee: CombinatoRx, Inc.Inventors: Alexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell
-
Patent number: 7008934Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more cyclodextrin derivatives, and if desired, one or more non-ionic surfactants such as the partial esters of sorbitol and the polyoxyethylene oxides of long chain fatty acids such as the polysorbates.Type: GrantFiled: June 26, 2002Date of Patent: March 7, 2006Assignee: Baxter International Inc.Inventor: Jianwei Yu
-
Patent number: 6982262Abstract: The present invention relates to the combination of cyamemazine and an atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular of acute episodes of schizophrenia.Type: GrantFiled: February 20, 2004Date of Patent: January 3, 2006Assignee: Aventis Pharma S. A.Inventors: Michel Dib, Cyrille Leperlier
-
Patent number: 6897199Abstract: The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.Type: GrantFiled: February 4, 2002Date of Patent: May 24, 2005Assignee: Dr. Reddy's Laboratories Ltd.Inventors: Om Reddy Gaddam, Ramabhadra Sarma Mamillapalli, Prabhakar Chebiyyam, Madhusudan Gutta
-
Patent number: 6846816Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.Type: GrantFiled: January 21, 2003Date of Patent: January 25, 2005Assignee: CombinatoRx, Inc.Inventors: Alexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell
-
Patent number: 6790463Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.Type: GrantFiled: March 30, 2001Date of Patent: September 14, 2004Inventors: Robert F. Hofmann, Robert H. Carpenter
-
Publication number: 20040171610Abstract: The present invention relates to the application of 2-cyano-10-(2-methyl-3-(methylamino)-propyl)phenothiazine or a pharmaceutically acceptable salt thereof to produce a medicament intended for the treatment of sleep disorders, anxiety disorders, mood disorders, mixed anxiety-depression disorder, acute and chronic psychotic state, addiction to and withdrawal from a substance, extrapyramidal events induced by antipsychotics, or symptomatic dimensions during acute or chronic psychotic states as monotherapy or in combination with other antipsychotics.Type: ApplicationFiled: February 6, 2004Publication date: September 2, 2004Applicant: Aventis Pharmaceuticals Inc.Inventors: Michel Dib, Ahcene Hameg
-
Patent number: 6780871Abstract: A method for treating an addiction disorder (such as an addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine, and/or alcohol) in a patient is disclosed. The method includes administering to the patient a first &agr;3&bgr;4 nicotinic receptor antagonist and administering to the patient a second &agr;3&bgr;4 nicotinic receptor antagonist. The second &agr;3&bgr;4 nicotinic receptor antagonist is different than the first &agr;3&bgr;4 nicotinic receptor antagonist, and the first &agr;3&bgr;4 nicotinic receptor antagonist and the second &agr;3&bgr;4 nicotinic receptor antagonist are administered simultaneously or non-simultaneously. Compositions which include a first &agr;3&bgr;4 nicotinic receptor antagonist and a second &agr;3&bgr;4 nicotinic receptor antagonist are also described.Type: GrantFiled: January 18, 2002Date of Patent: August 24, 2004Assignee: Albany Medical CollegeInventors: Stanley D. Glick, Isabelle M. Maisonneuve
-
Patent number: 6747024Abstract: The present invention relates to new heterocyclic derivatives having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species, of formula in which A, X, Y, R1, R2 and Het represent variable groups. The invention also relates to their preparation methods, the pharmaceutical preparations containing them and their use for therapeutic purposes, in particular as inhibitors of calpains and/or traps of reactive oxygen species, selectively or non-selectively.Type: GrantFiled: April 30, 2002Date of Patent: June 8, 2004Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Serge Auvin, Pierre-Etienne Chabrier de Lassauniere
-
Patent number: 6720318Abstract: The present invention relates to the combination of cyamemazine and an atypical neuroleptic, olanzapine or risperidone, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular, of acute episodes of schizophrenia.Type: GrantFiled: June 7, 2002Date of Patent: April 13, 2004Assignee: Aventis Pharma S. A.Inventors: Michel Dib, Cyrille Leperlier
-
Patent number: 6703401Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: November 27, 2001Date of Patent: March 9, 2004Assignees: Novo Nordisk A/S, Dr. Reddy's Research FoundationInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6686388Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating to consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.Type: GrantFiled: May 29, 2001Date of Patent: February 3, 2004Assignee: Curis, Inc.Inventors: Henryk Dudek, Benxiu Ji
-
Publication number: 20030199492Abstract: This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.Type: ApplicationFiled: May 19, 2003Publication date: October 23, 2003Inventor: Robert Andrew Donald Scott
-
Publication number: 20030166642Abstract: The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.Type: ApplicationFiled: January 21, 2003Publication date: September 4, 2003Inventors: Alexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell
-
Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
Patent number: 6593347Abstract: The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.Type: GrantFiled: August 27, 2001Date of Patent: July 15, 2003Assignee: NitroMed, Inc.Inventors: Upul K. Bandarage, Qing Dong, Xinqin Fang, David S. Garvey, Gregory J. Mercer, Stewart K. Richardson, Joseph D. Schroeder, Tiansheng Wang -
Patent number: 6583138Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.Type: GrantFiled: January 4, 2001Date of Patent: June 24, 2003Assignee: Eisai Co., Ltd.Inventors: Mitsuaki Miyamoto, Tatsuya Yoshiuchi, Keizo Sato, Motohiro Soejima, Takashi Sato, Koichi Kikuchi, Hiroyuki Yoshimura, Katsuhiro Moriya, Yoshinori Sakuma, Shigeru Akasofu, Koji Yamada
-
Patent number: 6569853Abstract: The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) chlorpromazine or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.Type: GrantFiled: November 6, 2000Date of Patent: May 27, 2003Assignee: CombinatoRx, IncorporatedInventors: Alexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell
-
Patent number: 6566389Abstract: A method for treating or preventing symptoms of tardive dyskensia comprises administering melatonin to patient exhibiting or liable to develop such symptoms. The melatonin is administered in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient.Type: GrantFiled: November 26, 2001Date of Patent: May 20, 2003Assignee: Neurim Pharmaceuticals (1991) Ltd.Inventors: Nava Zisapel, Moshe Laudon
-
Patent number: 6534500Abstract: The present invention relates to the use of cyamamazine, or the pharmaceutically acceptable salts thereof, in the treatment of abrupt benzodiazepine withdrawal.Type: GrantFiled: February 11, 2002Date of Patent: March 18, 2003Assignee: Aventis Pharma S.A.Inventor: Francoise D'Alché-Birée
-
Patent number: 6509335Abstract: This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnornal thrombosis.Type: GrantFiled: August 14, 2000Date of Patent: January 21, 2003Assignee: Warner-Lambert CompanyInventors: Kent Alan Berryman, Dennis Michael Downing, Danette Andrea Dudley, Jeremy John Edmunds, Lakshmi Sourirajan Narasimhan, Stephen Taras Rapundalo
-
Patent number: 6492332Abstract: This invention relates to a method of inhibiting tumor cell adhesion, pain, and inflammation at a wound during a surgical procedure by delivering an irrigation solution containing a tumor cell anti-adhesion agent and a plurality of additional agents to an operative site during the surgical procedure. In addition, methods of inhibiting tumor cell attachment and implantation during a surgical procedure as well as inhibiting tumor metastasis during a surgical procedure are also provided.Type: GrantFiled: September 11, 2000Date of Patent: December 10, 2002Assignee: Omeros CorporationInventors: Gregory A. Demopulos, Pamela Pierce-Palmer, Jeffrey M. Herz, Darrell L. Tanelian
-
Publication number: 20020177592Abstract: This invention discloses that a combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an &agr;2 adrenergic agonist, exemplified by clonidine. The other drug in the pain-relieving combination has a tri-cyclo-alkyl-amine (TCAA) structure. At least some TCAA drugs have antagonist (receptor-blocking) activity at two entirely different classes of neuronal receptors: the muscarinic subclass of acetylcholine (ACh) receptors, and the NMDA subclass of glutamate receptors. Such drugs include ethopropazine, normally used as an anti-cholinergic drug, and desipramine, normally used as an anti-depressant.Type: ApplicationFiled: March 28, 2001Publication date: November 28, 2002Inventors: John W. Olney, Nuri B. Farber, Vesna Jevtovic-Todorovic
-
Patent number: 6482822Abstract: The invention concerns novel N-(iminomethyl)amine derivatives comprising in their skeleton the aminophenylamine, oxodiphenylamine, carbazole, phenazine, phenoxazine or oxodiphenyl motif, their use as medicines and pharmaceutical compositions containing them. The invention concerns in particular the following compounds: -4-{[2-thienyl(imino)methyl]amino}-N-[2-(phenylamino)phenyl]-benzenebutanamide; -4-{[2-thienyl(imino)methyl]amino}-N-[4-(phenylamino)phenyl]-benzenebutanamide; -N-′[4-(10H-phenothiazin-2-yloxy)phenyl]-2-thiophenecarboximidamide; -4-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-(10H-phenothiazin-3-ylH)butanamide; -3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-(4-anilinophenyl)propanamide; -N′-(4-{2-[(10H-phenothiazin-3-ylmethyl)amino]ethyl}phenyl-2-thiophene carboximidamide.Type: GrantFiled: March 16, 2001Date of Patent: November 19, 2002Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)Inventors: Dennis Bigg, Pierre-Etienne Chabrier de Lassauniere, Serge Auvin, Jeremiah Harnett, Gérard Ulibarri
-
Publication number: 20020169146Abstract: The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.Type: ApplicationFiled: February 4, 2002Publication date: November 14, 2002Applicant: DR. REDDY'S LABORATORIES LTD.Inventors: Om Reddy Gaddam, Ramabhadra Sarma Mamillapalli, Prabhakar Chebiyyam, Madhusudan Gutta
-
Patent number: 6440961Abstract: A compound of formula (1) it derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, processes for its preparation and methods of use thereof.Type: GrantFiled: February 24, 1999Date of Patent: August 27, 2002Assignees: Dr. Reddy's Research Foundation, Reddy-Cheminor, Inc.Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Ashok Channaveerappa Bajji, Shivaramayya Kalchar, Rao Bheema Paraselli, Ranga Madhavan Gurram, Rajagopalan Ramanujam, Ranjan Chakrabarti
-
Publication number: 20020077320Abstract: Novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them.Type: ApplicationFiled: December 6, 2001Publication date: June 20, 2002Applicant: DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC.Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Ashok Channaveerappa Bajji, Shivaramayya Kalchar, Rajagopalan Ramanujam, Ranjan Chakrabarti
-
Patent number: 6365586Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: October 19, 1999Date of Patent: April 2, 2002Assignees: Novo Nordisk A/S, Dr. Reddy's Research FoundationInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6346529Abstract: A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to selectively inactivate or inhibit intracellular replication of specific viruses, especially human immunodeficiency virus. Examples of useful thiazine dyes are methylene blue, azure A, azure C, toluidine blue O, and thionine. The preferred dye at this time is methylene blue. Methylene blue is FDA approved for topical, i.v., and oral administration, and has minimal side effects. Since methylene blue absorbs in the red wavelengths, i.e., approximately 670 nm, which penetrates tissue much better than other lower wavelengths, light penetrating the skin to the capillaries at the surface can be used to enhance the activity of the dye.Type: GrantFiled: April 15, 1998Date of Patent: February 12, 2002Assignee: Oklahoma Medical Research FoundationInventors: Robert A. Floyd, Raymond F. Schinazi